Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Total Non-Current Liabilities: 2018-2024

Historic Total Non-Current Liabilities for Zevra Therapeutics (ZVRA) over the last 7 years, with Dec 2024 value amounting to $124.0 million.

  • Zevra Therapeutics' Total Non-Current Liabilities rose 2.78% to $119.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $119.5 million, marking a year-over-year increase of 2.78%. This contributed to the annual value of $124.0 million for FY2024, which is 20.41% up from last year.
  • According to the latest figures from FY2024, Zevra Therapeutics' Total Non-Current Liabilities is $124.0 million, which was up 20.41% from $103.0 million recorded in FY2023.
  • In the past 5 years, Zevra Therapeutics' Total Non-Current Liabilities registered a high of $124.0 million during FY2024, and its lowest value of $5.8 million during FY2021.
  • Its 3-year average for Total Non-Current Liabilities is $89.1 million, with a median of $103.0 million in 2023.
  • As far as peak fluctuations go, Zevra Therapeutics' Total Non-Current Liabilities plummeted by 92.52% in 2021, and later skyrocketed by 593.97% in 2022.
  • Yearly analysis of 5 years shows Zevra Therapeutics' Total Non-Current Liabilities stood at $77.5 million in 2020, then slumped by 92.52% to $5.8 million in 2021, then soared by 593.97% to $40.2 million in 2022, then surged by 156.26% to $103.0 million in 2023, then rose by 20.41% to $124.0 million in 2024.